Low-Dose Naltrexone Cardiovascular Impact: Long-Term Evidence and Clinical Guidance

Print or save as PDF

What low-dose naltrexone is, and why the heart question comes up

Low-dose naltrexone means naltrexone at 0.5 to 6 mg a day, most often 4.5 mg, used off-label for conditions such as fibromyalgia, multiple sclerosis, Crohn's disease and long COVID [1]. No LDN product or indication is FDA-approved [1][5]. The approved naltrexone products are 50 mg tablets for alcohol dependence and blockade of opioid effects, and a 380 mg gluteal injection given every four weeks for alcohol dependence and for prevention of relapse to opioid dependence [2][3].

Is there any long-term cardiovascular study of LDN?

A 2026 narrative review located 105 LDN studies, 15 of them randomized trials, across chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatology, post-infectious syndromes, mental health and oncology [1]. Cardiovascular disease and cardiovascular endpoints are not among the areas it covers.

The randomized LDN trials that do exist are small and short. They run from 31 to 99 patients, with follow-up from 8 weeks to 12 months, and their endpoints are pain, function, sleep, quality of life and, in Crohn's disease, mucosal healing [6][7][8][4][9][10]. The longest is a 12-month fibromyalgia trial of 4.5 mg daily in 98 women, whose primary outcome was change in pain intensity at 3 months [4]. An 8-week multiple sclerosis pilot enrolled 80 people, 60 completed, and the authors reported that dropout and data errors substantially reduced statistical power [9]. A review of LDN for long COVID searching to May 2026 identified no randomized trial at all, only four before-and-after observational studies totaling 155 people [11].

What the naltrexone labels record about the heart

In the opioid-addiction trials summarized in the 50 mg tablet label, cardiovascular events reported in less than 1% of subjects were nose bleeds, phlebitis, edema, increased blood pressure, non-specific ECG changes, palpitations and tachycardia [2]. Postmarketing reports listed in the same label include chest pain, hot flushes, changes in blood pressure and palpitations, and the label notes that most such events occur early in treatment and are transient [2].

For the injectable product, the 24-week opioid-dependence trial of 126 patients on naltrexone and 124 on placebo reported hypertension in 5% versus 3% [3]. The injection label's adverse-reaction table lists all treatment-emergent reactions regardless of causality [3].

These numbers come from 50 mg and 380 mg products; the labels give no guidance on LDN doses [2][1].

Does LDN reduce inflammation in a way that would protect the heart?

The mechanisms proposed for LDN, including Toll-like receptor 4 antagonism on microglia, brief opioid-receptor blockade with compensatory upregulation of endogenous opioid signaling, and opioid growth factor receptor effects, are described in a 2026 review as largely theoretical and speculative [1].

Cell experiments give a partial picture. In microglial and macrophage cell models, (+)-naltrexone, an opioid-inactive isomer rather than the opioid-blocking form used in medicines, blocked LPS-induced TLR4 signaling that produces nitric oxide and TNF-alfa, but did not directly inhibit IL-1beta production and did not act through NF-kappaB, p38 or JNK in those experiments [12].

Whether LDN reduces inflammation in people is unsettled. In a trial of 31 women, pain fell 28.8% from baseline with LDN and 18.0% with placebo (P=0.016) [6]. Larger later trials of 58, 98 and 99 patients did not beat placebo on their primary pain outcome [7][8][4], and a meta-analysis of four trials with 222 patients found pain scores lower by a mean of 0.86 points but no significant difference on the fibromyalgia impact questionnaire [13]. In the 10-woman pilot, a higher baseline erythrocyte sedimentation rate predicted more than 80% of the variance in response [14].

What the LDN trials recorded as side effects

Across trials, reported effects are mostly mild and transient: insomnia, vivid dreams, nausea and dizziness [1]. In the 12-month fibromyalgia trial, adverse events were reported by 68.8% of those on LDN and 72% on placebo, and no treatment-related serious events occurred [4]. The four-trial meta-analysis found more vivid dreams and nausea with LDN and no significant difference in serious adverse events [13].

Heart medicines, opioid painkillers and LDN

The 50 mg tablet label states that studies of interactions between naltrexone and drugs other than opioids have not been performed, so caution is advised if naltrexone is given with other drugs [2].

The opioid position is unambiguous. Naltrexone is contraindicated in patients receiving opioid analgesics and in patients currently dependent on opioids, including those maintained on methadone or buprenorphine, and the label names opioid-containing cough, cold and antidiarrheal preparations as medicines that naltrexone blocks [2][3]. The contraindication is written without a dose exception [2][1]. The labels also warn that opioid tolerance is lower at the end of an injection interval, after a missed dose or after treatment stops, and advise strongly considering prescribing naloxone or nalmefene [2][3].

The compounded product variable

LDN is commonly made as compounded capsules or liquid. FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed [1][5]. FDA also warns that poor compounding practices can result in a drug with too much or too little active ingredient, and a 2026 review notes that inconsistencies among compounded LDN formulations add uncertainty [5][1].